Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity
Daisy A. Hoagland, Rasmus Møller, Skyler Uhl, Kohei Oishi, Justin J. Frere, Ilona Golynker, Shu Horiuchi, Maryline Panis, Daniel Blanco-Melo, David Sachs, Knarik Arkun, Jean K. Lim, Benjamin R. tenOever
Topics & Concepts
BiologyVirologyPathogenicityInterferon type IFirst lineInterferonSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakMicrobiologyInfectious disease (medical specialty)DiseaseMedicineOutbreakPathologyInternal medicineSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesInfluenza Virus Research Studies